141 related articles for article (PubMed ID: 16088935)
1. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.
Teugels E; De Brakeleer S; Goelen G; Lissens W; Sermijn E; De Grève J
Hum Mutat; 2005 Sep; 26(3):284. PubMed ID: 16088935
[TBL] [Abstract][Full Text] [Related]
2. Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families.
Montagna M; Santacatterina M; Torri A; Menin C; Zullato D; Chieco-Bianchi L; D'Andrea E
Oncogene; 1999 Jul; 18(28):4160-5. PubMed ID: 10435598
[TBL] [Abstract][Full Text] [Related]
3. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
Preisler-Adams S; Schönbuchner I; Fiebig B; Welling B; Dworniczak B; Weber BH
Cancer Genet Cytogenet; 2006 Jul; 168(1):44-9. PubMed ID: 16772120
[TBL] [Abstract][Full Text] [Related]
4. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
5. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
6. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Maillet P; Chappuis PO; Khoshbeen-Boudal M; Sciretta V; Sappino AP;
Cancer Genet Cytogenet; 2006 Aug; 169(1):62-8. PubMed ID: 16875939
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Pavlicek A; Noskov VN; Kouprina N; Barrett JC; Jurka J; Larionov V
Hum Mol Genet; 2004 Nov; 13(22):2737-51. PubMed ID: 15385441
[TBL] [Abstract][Full Text] [Related]
8. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
9. Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
Konstantopoulou I; Rampias T; Ladopoulou A; Koutsodontis G; Armaou S; Anagnostopoulos T; Nikolopoulos G; Kamakari S; Nounesis G; Stylianakis A; Karanikiotis C; Razis E; Gogas H; Keramopoulos A; Gaki V; Markopoulos C; Skarlos D; Pandis N; Bei T; Arzimanoglou I; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Feb; 107(3):431-41. PubMed ID: 17453335
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations.
Agata S; Viel A; Della Puppa L; Cortesi L; Fersini G; Callegaro M; Dalla Palma M; Dolcetti R; Federico M; Venuta S; Miolo G; D'Andrea E; Montagna M
Genes Chromosomes Cancer; 2006 Sep; 45(9):791-7. PubMed ID: 16715518
[TBL] [Abstract][Full Text] [Related]
12. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
13. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
[TBL] [Abstract][Full Text] [Related]
14. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
15. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
16. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
17. Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
Armaou S; Konstantopoulou I; Anagnostopoulos T; Razis E; Boukovinas I; Xenidis N; Fountzilas G; Yannoukakos D
Eur J Cancer; 2007 Jan; 43(2):443-53. PubMed ID: 17174087
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
19. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
van der Hout AH; van den Ouweland AM; van der Luijt RB; Gille HJ; Bodmer D; Brüggenwirth H; Mulder IM; van der Vlies P; Elfferich P; Huisman MT; ten Berge AM; Kromosoeto J; Jansen RP; van Zon PH; Vriesman T; Arts N; Lange MB; Oosterwijk JC; Meijers-Heijboer H; Ausems MG; Hoogerbrugge N; Verhoef S; Halley DJ; Vos YJ; Hogervorst F; Ligtenberg M; Hofstra RM
Hum Mutat; 2006 Jul; 27(7):654-66. PubMed ID: 16683254
[TBL] [Abstract][Full Text] [Related]
20. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
